Advertisement

Addition of Bortezomib to Chemotherapy in Newly Diagnosed T-Cell Lymphoblastic Lymphoma (T-LL) and T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Posted: 03/15/2022 | By: Matthew Stenger

Question 1 of 5

Four-year event-free survival with vs without bortezomib was:

Choose 1